叶酸修饰纳米载体抑制P糖蛋白改善肿瘤耐药的研究进展  

Research progress of folate functionalized nanoparticles in diverting P-glycoprotein mediated drug efflux

作　　者：李璟寰[1] 任正刚[1] 

机构地区：[1]复旦大学附属中山医院肝肿瘤内科肝癌研究所癌变与侵袭原理教育部重点实验室,上海200032

出　　处：《肿瘤研究与临床》2015年第7期502-504,共3页Cancer Research and Clinic

摘　　要：化疗仍然是许多肿瘤患者的主要治疗手段。但是，P糖蛋白（P-gp）介导的多药耐药对化疗提出了严峻的挑战。靶向纳米载体的运用使抑制或绕过P-gp成为可能。叶酸受体在肿瘤组织中表达量高，且叶酸具有稳定性好、无毒性及免疫原性等优势，使得叶酸在纳米载体的修饰中被广泛应用。文章就叶酸修饰的靶向纳米药物载体在抑制P-gp中的应用进行综述。Chemotherapy remains the main treatment for many cancer patients. However, P-glycoprotein （P-gp） mediated multidrug resistance poses severe challenges to current chemotherapies. As ideal vectors to overcome drug resistance, nanovehicles are extensively explored for cancer treatment by diverting P-gp mediated drug efflux mechanisms. Surface engineering of nanocarriers has attracted great attention for targeted therapeutic delivery. The folate receptors, one of the most researched targets in cancer therapeutics, are over-expressed in several carcinomas. And folate has become one of the most investigated ligands in cancer therapeutic direction due to its small size, easy conjugation to nanocarriers, nontoxic, nonimmunogenic nature, and well stability in storage or in circulation. This review discussed the current status of folate functionalized nanoparticles in diverting P-gp mediated drug efflux mechanisms.

关 键 词：肿瘤耐药 P糖蛋白 纳米载体 叶酸 

分 类 号：R730.53[医药卫生—肿瘤]